Stock comparison
LeMaitre Vascular
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 71B | LMAT |
| Benjamin Graham | 89A | 76B | LMAT |
| Philip Fisher | 81C | 76B | LMAT |
| Peter Lynch | 67B | 62C | LMAT |
| Joel Greenblatt | 56D | 46D | LMAT |
| Charlie Munger | 68D | 64C | LMAT |
| Terry Smith | 69D | 64C | LMAT |
Side-by-side metrics
| Metric | LMAT | UTHR |
|---|---|---|
| Market cap | $2.23B | $24.13B |
| P/E (TTM) | 37.1x | 19.2x |
| EV/EBIT | 36.6x | 15.2x |
| ROIC (TTM) | 9.43% | 18.81% |
| Gross margin | 72.39% | 86.58% |
| Net margin | 24.35% | 40.61% |
| Revenue CAGR 5y | 12.75% | 17.22% |
| EPS CAGR 5y | 19.04% | 29.84% |
| Debt / Equity | 0.5x | - |
| Dividend yield | 0.84% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
UTHR leads on
- Debt / Equity-vs 0.5x+100%
- Market cap$24.13Bvs $2.23B+91%
- EV/EBIT15.2xvs 36.6x+58%
- ROIC (TTM)18.81%vs 9.43%+50%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.